Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Arash Asher, MD
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosed with cancer, stage 1-4.
Completed taxane- or platinum-based chemotherapy at least three months (90 days) ago but within 24 months of signing consent. Current use of anti-estrogen therapy, Herceptin, or PARP inhibitors is okay.
Experiencing at least grade 1 peripheral sensory neuropathy, peripheral motor neuropathy, or dysesthesias based on the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4 (NCI CTCAE v4.0).
Age ≥ 18 years.
Concomitant use of analgesics is permitted if the dose has been stable for at least 2 weeks prior to study enrollment (no new analgesics have been added, discontinued, or changed in the 2 weeks prior to study enrollment).
Reasonable functional stability as assessed by the evaluating physician.
Must be able to understand and communicate proficiently in English.
Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.
You may not be if
Syphilis, alcoholic neuropathy, diabetic neuropathy, neurological disorders, brain injury, or stroke, as assessed by the treating physician.
Medical history of neuropathy from any type of nerve compression (e.g., carpal tunnel or tarsal tunnel syndrome, radiculopathy, spinal stenosis, brachial plexopathy, leptomeningeal carcinomatosis), as assessed by the treating physician.
Neuropathy related to abnormal TSH or B12 levels as assessed by treating physician
Current severe depression, suicidal ideation, bipolar disease, alcohol abuse, or major eating disorder, as assessed by the treating physician.
Severe personality disorder or psychiatric disorder that would interfere with participation in a QiGong program, as assessed by the evaluating physician.
Currently participating in another QiGong or Tai Chi program.
Clareo Health | A Mind-Body Intervention for Chemotherapy-Induced Peripheral Neuropathy
